Dyne Therapeutics, Inc. filings document regulatory disclosures for a clinical-stage neuromuscular disease company advancing FORCE platform programs. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary cash-resource disclosures, investor presentation materials, clinical and FDA-related updates, and other business highlights tied to Duchenne muscular dystrophy and myotonic dystrophy type 1 programs.
The company’s definitive proxy materials cover board structure, director elections, executive compensation, equity awards, stockholder voting matters and governance practices. Other filings address board appointments, non-employee director compensation arrangements and Nasdaq-related inducement equity awards.
Dyne Therapeutics, Inc. is asking stockholders to approve several items at its virtual 2026 annual meeting on June 5, 2026. Proposals include electing three Class III directors for terms through 2029, an advisory “say‑on‑pay” vote on executive compensation, and ratifying Deloitte & Touche LLP as auditor for 2026.
The company also seeks to amend its Restated Certificate of Incorporation to increase authorized common stock from 200,000,000 to 400,000,000 shares and to add officer exculpation protections. The record date is April 7, 2026, when 165,219,501 common shares were outstanding, and all voting will occur online via a registered virtual platform.
Dyne Therapeutics, Inc. director-affiliated investment funds reported open-market sales of a combined 834,302 shares of common stock over April 20–22, 2026. The transactions were executed at weighted-average prices generally between $19.035 and $20.354 per share.
The shares are held indirectly through Atlas Venture funds and related general partners, and the reporting person Jason P. Rhodes disclaims Section 16 beneficial ownership except for any pecuniary interest. The sales were made pursuant to a Rule 10b5-1 trading plan adopted on March 19, 2026.
DYN insiders reported proposed sales of 143,749 shares of Common stock under Form 144. The filing lists multiple selling holders with recent transactions: Atlas Venture Fund XI proposed 142,571 shares for $2,859,490.52, Atlas Venture Opportunity Fund II proposed 71,722 shares for $1,438,499.97, Atlas Venture Opportunity Fund I proposed 56,355 shares for $1,130,290.09, and Atlas Venture Associates XI proposed 1,401 shares for $28,099.31.
DYN affiliates reported proposed resale of Common Stock under Rule 144 by multiple Atlas Venture entities, with recent sales reported on 04/20/2026. The filing lists per-holder transactions: 142,571 shares ($2,859,490.52), 71,722 shares ($1,438,499.97), 56,355 shares ($1,130,290.09), and 1,401 shares ($28,099.31).
DYN notice reports proposed resale of Common Stock by several Atlas Venture funds. The excerpt lists four selling entities proposing sales on 04/20/2026 with specified share amounts and gross proceeds. The transactions are identified as sales of restricted securities from a prior Private Placement.
DYN filed a Form 144 reporting proposed affiliate sales of Common Stock and disclosing recent dispositions.
The filing references securities issued in a Private Placement dated 04/26/2019 and lists recent sales on 04/20/2026 by Atlas Venture entities, including Atlas Venture Fund XI, LP: 142,571 shares for $2,859,490.52 and Atlas Venture Opportunity Fund II, L.P.: 71,722 shares for $1,438,499.97.